Saturday 17 October 2026 Export OGN’s income statement to Excel — free account

Organon & Co.

OGN Healthcare Drug Manufacturers General

Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024. In the quarter to June 2026, revenue fell 2.26%, EPS fell 26.8%, free cash flow fell 83.0% and total debt fell 3.86%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

13.76 0.00 0.00%

Follow OGN

Alert me

Market cap: $3.6B
P/E: 17.4×
Fwd P/E: 5.2×
Dividend yield: 0.58%
F-score: 5/9
Altman Z: 1.09
Beneish M: −2.68
Dividend safety: 45/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.50

Total sells 0.55

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	1	—	—	1	—	—

Insider Ownership 0.64%

Capital & Financial Ratios $m

Market Cap 3,610.00

Revenue 6,127.00

Net Income 209.00

Free Cash Flow 464.00

Net Debt 7,421.00

Current Ratio 1.95

Debt/Equity 8.50

P/E ratio 17.42

Fwd P/E 5.22

P/S ratio 0.59

P/B ratio 3.59

Past 5Y EPS Growth (38.99%)

This Y EPS Growth (8.47%)

Next Y EPS Growth 8.36%

Next Y revenue growth (0.76%)

Next 5Y EPS Growth 3.09%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 99.41%

10-year low 10-year high

P/S against its own 10 years 31.55%

10-year low 10-year high

EV/Sales against its own 10 years 29.71%

10-year low 10-year high

EV/FCF against its own 10 years 59.57%

10-year low 10-year high

Dividends

Payout Ratio 0.10

Annual Dividend Rate 0.08

Annual Dividend Yield 0.58%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	0.08	0.02 0.02 0.02
2025	0.34	0.28 0.02 0.02 0.02
2024	1.12	0.28 0.28 0.28 0.28
2023	1.12	0.28 0.28 0.28 0.28
2022	1.12	0.28 0.28 0.28 0.28
2021	0.56	0.28 0.28

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	693	675	574	1,132
Receivables	1,744	1,358	1,331	1,492
Inventory	1,315	1,321	1,406	1,351
Other	756	994	1,041	1,136
	4,508	4,348	4,352	5,111

	2023	2024	2025	Q'26
Payables	1,314	1,153	952	1,051
ST’ Debt	9	20	16	74
Other	—	—	2	—
	2,918	2,718	2,390	2,616

Compound Annual Growth %

	10y	5y	3y
Sales	—	(0.99%)	0.23%
Cash Flow	—	(21.06%)	(6.56%)
Earnings	—	(38.70%)	(41.14%)
Book Value	—	(32.80%)	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1,460	1,558	—	—	—
’25	1,513	1,594	1,602	1,507	6,216
’24	1,622	1,607	1,582	1,592	6,403
’23	1,538	1,608	1,519	1,598	6,263
’22	1,567	1,585	1,537	1,485	6,174
’21	1,506	1,595	1,600	1,603	6,304
’20	1,780	1,526	1,613	1,613	6,532

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	225	107	—	—	—
’25	75	220	264	141	700
’24	76	332	141	390	939
’23	114	27	261	397	799
’22	123	151	317	267	858
’21	1,300	445	368	47	2,160
’20	747	733	320	387	2,284

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	188	31	—	—	—
’25	(12)	182	149	96	415
’24	(20)	301	77	305	663
’23	68	(43)	206	316	547
’22	60	68	209	208	545
’21	1,262	388	140	(7)	1,783
’20	708	686	275	260	2,034

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.55	0.40	—	—	—
’25	0.33	0.56	0.61	(0.79)	0.72
’24	0.78	0.75	1.38	0.42	3.33
’23	0.69	0.95	0.23	2.13	3.99
’22	1.36	0.92	0.89	0.42	3.59
’21	1.58	1.68	1.27	0.79	5.31
’20	2.77	2.14	2.16	1.45	8.52

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	27.25	22.88	10.84	13.65	6.18	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	38.75	39.48	32.43	23.10	17.23
People
People	Employees	—	—	—	—	9,950	9,300	10,000	10,000	4,000	10,000
	Revenue/emp, $m	—	0.00	0.00	0.00	0.66	0.68	0.62	0.63	1.60	0.62
Income, $m
Income, $m	Revenue	—	10,500	9,777	7,777	6,532	6,304	6,174	6,263	6,403	6,216
	Gross margin, %	—	56.30	52.00	70.76	67.56	62.21	62.84	59.84	58.02	53.30
	EBT	—	3,099	2,729	3,696	2,752	1,529	1,122	673	807	425
	EBT margin, %	—	29.51	27.91	47.52	42.13	24.25	18.17	10.75	12.60	6.84
	Net income	—	0	2,153	3,306	2,256	0	917	1,023	864	187
	Depreciation	—	1,973	1,673	333	142	195	212	236	288	612
Per share, $
Per share, $	Revenue	—	41.50	38.64	30.68	25.77	24.86	24.30	24.54	24.91	23.95
	Earnings	—	7.11	8.51	12.69	8.52	5.33	3.61	4.01	3.36	0.72
	Cash flow	—	13.51	14.57	11.91	9.01	8.52	3.38	3.13	3.65	2.70
	Capex	—	0.00	(0.27)	(0.35)	(0.99)	(1.49)	(1.23)	(0.99)	(1.07)	(1.10)
	Free cash flow	—	13.51	14.30	11.57	8.02	7.03	2.15	2.14	2.58	1.60
	Book value	—	0.00	0.00	27.75	21.64	(5.95)	(3.51)	(0.27)	1.84	2.90
	Shares, m	—	253	253	254	254	254	254	255	257	259
Valuation, ×
Valuation, ×	P/E	—	4.54	4.54	4.54	4.54	5.71	7.80	3.66	4.45	9.96
	P/S	—	1.35	1.35	1.35	1.35	1.22	1.16	0.60	0.60	0.30
	P/B	—	1.79	1.79	1.79	1.79	0.00	0.00	0.00	8.13	2.47
	EV/Sales	—	1.49	1.49	1.49	1.49	2.56	2.48	1.89	1.88	1.60
	EV/FCF	—	3.76	3.76	3.76	3.76	8.16	28.15	26.10	18.16	23.93
Cash, $m
Cash, $m	Operating cash flow	—	3,419	3,687	3,020	2,284	2,160	858	799	939	700
	Capex	—	(86)	(69)	(88)	(250)	(377)	(313)	(252)	(276)	(285)
	Free cash flow	—	3,419	3,618	2,932	2,034	1,783	545	547	663	415
Balance, $m
Balance, $m	Working capital	—	—	2,169	2,614	894	1,163	1,419	1,590	1,630	1,962
	Total debt	—	—	149	118	31	9,134	8,913	8,760	8,880	8,644
	Net debt	—	—	(95)	(201)	19	8,397	8,207	8,067	8,205	8,070
	Shareholders’ equity	—	—	—	7,035	5,486	(1,508)	(892)	(70)	472	752
Returns, %
Returns, %	ROA	—	0.00	0.00	61.02	20.91	13.00	8.48	8.89	6.87	1.44
	ROIC	—	—	0.00	33.80	31.74	16.25	13.41	9.82	9.90	5.84
	ROE	—	0.00	32.18	48.09	34.50	67.92	(76.42)	(212.68)	429.85	30.56

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PFE Pfizer Inc.	$167.8B	38.9×	12.2×	+2.60% (above 0%: growing)	n/m	+125.17% (above 0%: growing)	72.78%	20.38%	Compare
NVO Novo Nordisk A/S	$131.2B	9.5×	—	+4.47% (above 0%: growing)	−18.68% (below 0%: shrinking)	+71.57% (above 0%: growing)	78.21%	34.48%	Compare
BMY Bristol Myers Squibb Company	$123.7B	13.2×	11.2×	+5.74% (above 0%: growing)	+153.13% (above 0%: growing)	−13.16% (below 0%: shrinking)	71.28%	31.50%	Compare
GSK GSK PLC Sponsored ADR	$98.2B	15.4×	12.4×	+5.81% (above 0%: growing)	−69.47% (below 0%: shrinking)	+54.83% (above 0%: growing)	73.05%	5.72%	Compare
SNY Sanofi	$96.0B	21.3×	—	+17.35% (above 0%: growing)	−90.76% (below 0%: shrinking)	−45.06% (below 0%: shrinking)	75.47%	17.48%	Compare
BIIB Biogen Inc.	$34.8B	41.0×	31.5×	+3.42% (above 0%: growing)	−84.76% (below 0%: shrinking)	+103.28% (above 0%: growing)	71.60%	5.52%	Compare
OGN Organon & Co.	$3.6B	17.4×	5.2×	−2.26% (below 0%: shrinking)	−26.79% (below 0%: shrinking)	−82.97% (below 0%: shrinking)	54.36%	20.67%
GRFS Grifols, S.A.	$2.0B	8.5×	—	+5.76% (above 0%: growing)	+466.92% (above 0%: growing)	+300.52% (above 0%: growing)	36.47%	14.76%	Compare
AMRN Amarin Corporation PLC	$244.4M	— (loss-making)	— (loss-making)	−41.97% (below 0%: shrinking)	n/m	−60.23% (below 0%: shrinking)	35.51%	(28.45%)	Compare
Median of peers	$97.1B	15.4×	12.3×	+5.11%	−44.07%	+63.20%	72.19%	16.12%

All 21 Drug Manufacturers General stocks →

Organon & Co. (OGN) key facts

Concern: Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
Concern: Net income was $187.0 million, or $0.72 per share (basic), a net margin of 3.01%.
Organon & Co. (OGN) is a Drug Manufacturers General company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, OGN traded at $13.76, a market capitalization of $3.6 billion.
At that price the stock trades at 17.4× trailing-twelve-month earnings and 0.6× sales; its P/E is higher than 99% of its own readings over the past ten years.
Organon & Co. pays an annual dividend of $0.08 per share, a yield of 0.58%, with a payout ratio of 10.4%.
Return on equity was 30.6% and debt-to-equity 8.50.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 1.09 (distress zone) for fiscal 2025.